Catalyst Pharmaceuticals Partners, Inc. Cash Flow Statement
CPRX / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Catalyst Pharmaceuticals Partners, Inc. generated $209M in operating cash flow and $209M in free cash flow in FY2025. Free cash flow margin was 35.4% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 4.78 (safe zone, above 2.9 threshold)
- Strong profit margin: 33.3%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $214.3M | $163.9M | $71.4M | $83.1M | $39.5M | $75.0M | $31.9M | -$34.0M | -$20.2M | -$18.1M | -$20.2M | -$15.5M | -$12.2M | -$4.1M | -$6.4M |
| Depreciation & Amortization | $375.0K | $397.0K | $316.0K | $141.0K | $192.0K | - | - | - | $34.5K | $43.4K | $34.5K | $26.6K | $22.5K | $10.9K | $42.8K |
| Operating Cash Flow | $208.7M | $239.8M | $143.6M | $116.0M | $60.4M | $45.0M | $34.6M | -$26.1M | -$18.0M | -$18.0M | -$18.0M | -$12.9M | -$9.9M | -$5.1M | -$5.0M |
| Capital Expenditures | $58.0K | $556.0K | $231.0K | $29.0K | $1.0M | $11.0K | $19.0K | $92.0K | $23.5K | $96.1K | $23.5K | $57.3K | $9.4K | $52.4K | $3.6K |
| Free Cash Flow | $208.6M | $239.3M | $143.4M | $116.0M | $59.4M | $45.0M | $34.6M | -$26.2M | -$18.0M | -$18.1M | -$18.0M | -$13.0M | -$9.9M | -$5.2M | -$5.0M |
| Share Buybacks | $25.3M | $0 | $0 | $6.9M | $12.1M | - | - | - | - | - | - | - | - | - | - |
| FCF Margin | 35.4% | 48.6% | 36.0% | 54.2% | 42.1% | 37.8% | 33.8% | -5247.9% | - | - | - | - | - | - | - |